Novo Nordisk

There were three big companies that initiated the creation of that standard.

Nova Nordisk, Sanofi, and Eli Lilly.

And the reason that a pen is so important to those three companies is because they deliver insulin and insulin needs to get in you ASAP, right? Same thing with epinephrine.

They put those kinds of drugs, they can put them in any other delivery system, but the problem warrants the delivery system in those cases.

Yeah, there are at least two others.

One is Novo Nordisk's zanagamtide, which is a dual agonist targeting GLP-1 as well as amylin, a pancreatic beta cell peptide hormone that's involved in satiety.

The other one is almorelin tide, another amylin agonist, which Lilly is testing alone and in combination with its approved dual agonist tirzepatide, which is marketed as Zepbound.

People have been talking online about buying almorelin tide and stacking it, which is peptide user lingo for combining it with a GLP-1 receptor agonist.

And preventing the bad things like strokes and heart attacks and heart failure.

Which, by the way, is not necessarily true because, for example, we just had a Novonordisk drug that kind of crashed and burned on the launch pad because it was designed to lower LPA.

Oh, right, right, right, right, right.

Well, that's an excellent...

Some firms are securing substantial funding rounds, while others face operational challenges leading to shutdowns.

Regulatory hurdles persist as well, exemplified by Novo Nordisk's delayed US approval for Frihemgo due to manufacturing issues.

Shionogi's recent actions underscore this dynamic landscape with its two billion dollars acquisition of IntraBio to bolster its rare disease unit beyond anti-infectious disease therapies.

This strategic pivot aligns with FDA label expansions and reflects Shionogi's resolve to diversify therapeutic offerings.

So right, so four drugs from the twenty-six cohort are out because there's competition.

That's gonna be, um, Novartis' Entresto, Johnson & Johnson's Stelara and Xarelto, Novo Nordisk's Novolog, uh, and Fiasp.

Is that how you say that? That, that, like, came out after I-

Fi- Fi- Fiasp?

They never, they haven't stated.

Anyway, III 40 Report actually reached out to the two manufacturers who didn't submit.

That's Novo Nordisk and Astra, and they got a, a nice summary that, um, you know, Novo kind of had a, a discussion point, um, still remains committed to compliance and program, but also everything else.

But think about the drug they didn't seek a rebate on.

the dominance that they have right now as it relates to obesity and weight loss drugs is really staggering.

Um, while I'm speaking, if we could show a chart of Novo Nordisk, I think what you'll see-

Sure

... is year to date, you have Lilly, uh, up 10% and you have Novo down, I think somewhere around 24%.

In exchange, CEO David Ellison will, among other things, spend $300 million more annually on domestic production for the next five years.

Lastly, Novo Nordisk bulks up.

The company plans at least five new blockbuster drugs by the end of the decade.

The Ozembic maker aims to have about a dozen candidates in late stage trials by 2030 with weight loss medications still front and center.